April 22, 2012

A lot has happened across GlaxoSmithKline’s consumer division in the past year. Drug Store News spoke with GSK Consumer chief marketing officer John Graham and chief customer officer Keith Loranger about the next move to be made out of the consumer division’s new playbook.

December 18, 2014

The U.S. Senate Special Committee on Aging unveiled a new bipartisan report earlier this week that focuses on ways to increase the use of generic drugs within the Medicare Part D program.

December 17, 2014

The Generic Pharmaceutical Association on Wednesday expressed concerns that the current structure of the Trans-Pacific Partnership agreement (TPP) will impede generic utilization.

December 11, 2014

After a recent spike in the prices charged for some generic drugs led to outcries from pharmacists, patient advocates and federal lawmakers, a report issued last month suggests that drug costs can be controlled if the Food and Drug Administration changes the way it handles reviews and approvals.

 
December 10, 2014

Teva Pharmaceutical Industries on Wednesday announced the launch of generic Celebrex (celecoxib) capsules in the United States. The company is offering the capsules in 50-,100-, 200- and 400-mg dosage strengths. 

 

December 9, 2014

Reps. Doug Collins, R-Ga., and Dave Loebsack, D-Iowa, introduced on Tuesday H.R. 5815 — the Generic Drug Pricing Fairness Act — which creates greater transparency in how PBMs reimburse pharmacies for generic prescription drugs under Medicare Part D, the military’s TRICARE program, and the Federal Employees Health Benefits Program.

December 9, 2014

Teva Canada, a subsidiary of Teva Pharmaceutical Industries, announced Tuesday that Health Canada has approved its application for the generic version of PrTarceva. 

December 5, 2014

The FDA issued a draft guidance that would provide generic companies a pathway to obtain samples of medicines requiring a Risk Evaluation and Mitigation Strategy (REMS) protocol for product testing.

December 3, 2014

Health-and-wellness companies see increasing opportunity in the point-of-care channel to reach and engage with patients primed to receive information about their health.

 

December 2, 2014

The Generic Pharmaceutical Association on Tuesday announced that it has named Terry Bazyluk as VP communications, effective Dec. 1, 2014. Bazyluk has served in senior communications roles for trade associations, corporate CEOs and presidential cabinet secretaries Madeleine Albright, Colin Powell and Robert Reich.

December 1, 2014

GlaxoSmithKline last week announced that the Federal Trade Commission has approved GSK's acquisition of Novartis' vaccines business and the creation of a joint consumer care company between GSK and Novartis.

 

November 20, 2014

The Generic Pharmaceutical Association on Thursday emphasized the savings generic medicines bring to the table in light of rising brand prices. 

November 20, 2014

Moberg Pharma AB on Thursday announced that Jeff Vernimb has been named general manager for its U.S. operations and a member of Moberg's management team, effective Dec. 15.

 

November 19, 2014

The Food and Drug Administration opened a public docket and requested comments on proposed criteria for “first generic” abbreviated new drug application submissions.

 

November 17, 2014

DSN spoke with Neas in late October to mark the 30th anniversary of the landmark Drug Price Competition and Patent Term Restoration Act — better known as the Hatch-Waxman Act. 

November 17, 2014

Thirty years ago, Democratic and Republican members of Congress hammered out a rare and prescient bipartisan compromise bill that transformed the pharmaceutical landscape forever and unleashed the modern generic drug industry. That law, known as the Hatch-Waxman Act, has proven to be one of the most far-reaching and impactful pieces of legislation ever to shape the American healthcare system.

November 17, 2014

Pharmaceutical sales through HDMA-member traditional primary distributors reached nearly $305 billion in 2013.

November 3, 2014

The RAND Corp. projected that the introduction of biosimilar drugs in the United States will reduce direct spending on biologics by $44.2 billion from 2014 to 2024.

 

October 31, 2014

The response to the current global Ebola scare from both the pharmaceutical and pharmacy industries has been nothing short of remarkable. Precautionary preparations have been made to address the Ebola concerns in the United States; several pharmaceutical manufacturers have been working around the clock toward an Ebola vaccine and treatment; and there has been an outpooring of goods that have been directed to help with the outbreak in West Africa. 

Ebola is not a problem in the United States, at least not yet (nor hopefully will it ever be), but the pharmaceutical community is stepping up to help around the world. And in the U.S., there is much being done to help the pharmacy world prepare.

 

October 24, 2014

In the wake of an Oct. 21 blogpost on Health Affairs, “The $500 Billion Medicare Slowdown: A Story About Part D,” Ralph Neas, president and CEO of the Generic Pharmacuetical Association, issued the following statement.

October 22, 2014

The Food and Drug Administration last week announced plans to survey pharmacists and patients about their experiences resulting from changes in generic drug pill appearance.

October 22, 2014

The pharmaceutical industry has committed considerable resources to developing both vaccines and treatments to address the current Ebola crisis.

 

October 15, 2014

Camber Consumer Care, which focuses on both consumer care and prescription-to-OTC switch products, recently introduced new executives to its staff.

October 15, 2014

The U.S. Supreme Court on Wednesday heard arguments from Teva Pharmaceutical Industries in defense of the patent protecting its $4 billion multiple sclerosis drug Copaxone, according to a Reuters report.